Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Avrobio Inc (NQ: AVRO ) 1.200 +0.010 (+0.84%) Streaming Delayed Price Updated: 11:42 AM EDT, Apr 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Avrobio Inc < Previous 1 2 3 Next > BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB) February 26, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB) February 16, 2024 From Brodsky & Smith LLC Via GlobeNewswire AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO February 14, 2024 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ZeroFox Holdings, Inc. (Nasdaq – ZFOX), AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF) February 06, 2024 From Brodsky & Smith LLC Via GlobeNewswire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX) January 30, 2024 From Brodsky & Smith LLC Via GlobeNewswire AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders January 30, 2024 From Halper Sadeh LLC Via Business Wire AVROBIO and Tectonic Therapeutic Announce Merger January 30, 2024 From AVROBIO, Inc. Via Business Wire AVROBIO to Explore Strategic Alternatives July 12, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million June 12, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million May 22, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting May 18, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Leadership Transition May 01, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update March 23, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference March 03, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023 February 09, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 05, 2023 From AVROBIO, Inc. Via Business Wire AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy December 07, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO to Share Comprehensive Gaucher Disease Program Update November 17, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update November 08, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit November 07, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 03, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease October 27, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis October 25, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease October 18, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development October 11, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 06, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress September 27, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis September 20, 2022 From AVROBIO, Inc. Via Business Wire AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial September 14, 2022 From AVROBIO, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.